Primary Results From the Phase 3 SHINE Study of Ibrutinib in Combination With Bendamustine-Rituximab and R Maintenance as a First-Line Treatment for Older Patients With Mantle-Cell Lymphoma

Download

Download poster

 Download

Download ASCO oral presentation

 Download

Read N Engl J Med article

Poster presented at the

XXV Congress of the Polish Society of Clinical Oncology, September 1-3, 2022, Gdansk, Poland.

Authors

Wojciech Jurczak, Steven Le Gouill, Mats Jerkeman, Judith Trotman, Pier Luigi Zinzani, David Belada, Carola Boccomini, Ian W. Flinn, Pratyush Giri, Andre Goy, Paul A. Hamlin, Olivier Hermine, José-Ángel Hernández-Rivas, Xiaonan Hong, Seok Jin Kim, David Lewis, Yuko Mishima, Muhit Özcan, Guilherme Fleury Perini, Christopher Pocock, Yuqin Song, Stephen E. Spurgeon, John M. Storring, Jan Walewski, Jun Zhu, Rui Qin, Todd Henninger, Sanjay Deshpande, Angela Howes, Martin Dreyling, Michael L. Wang

This site is intended for attendees of the congress where the research is presented and limited to healthcare professionals. IMBRUVICA (Ibrutinib) is an inhibitor of Bruton’s tyrosine kinase (BTK), jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc. This site contains scientific presentations on investigational products and/or investigational uses of approved products for Janssen-sponsored studies. The safety and efficacy of these investigational products and/or investigational uses of approved products has not been established and there is no guarantee that such investigational products/uses will be filed with and/or approved for marketing by any health authority. Marketing authorization, approval status, and prescribing information for approved products varies by country. Please see information made available by the health authority in your country such as approved product labeling. Contains other materials licensed/used with permission. Copies of these posters/oral presentations obtained through Quick Response (QR) Codes are for personal use only and may not be reproduced without permission from the congress or the author of the poster or oral presentation.